Comparing 3 Schedules of Alimta Plus Gemzar

Phase 2

Completed

• Conditions: Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neoplasms

• Registration Number: NCT00034606
• Lead Sponsor: Eli Lilly and Company

Brief Summary

The purpose of the study is to measure tumor response rates for three schedules of Alimta(LY231514) in combination with gemcitabine in patients with locally advanced or metastatic non small cell lung cancer who have received no prior chemotherapy regimen.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2002-05-01
• Study First Submitted QC: 2002-05-01
• Study First Posted: 2002-05-02
• Status Verified: 2006-07
• Last Update Submitted: 2006-07-18
• Last Update Posted: 2006-07-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Diagnosis of non-small lung cancer
• No prior chemotherapy
• Able to care for self

Exclusion Criteria

• An ongoing infection
• Pregnancy or breast feeding
• Other serious medical condition
• Cancer that has spread to the brain
• Inability to take folic acid

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL